Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531.
Erin K BarrArlene NaranjoClare J TwistSheena C TenneyMary Lou SchmidtWendy B LondonJulie Gastier-FosterE Stanton AdkinsPeter MatteiMichael H HandlerKatherine K MatthayJulie R ParkJohn M MarisAmi V DesaiSusan L CohnPublished in: Pediatric blood & cancer (2024)
The ANBL0531 trial treatment algorithm resulted in excellent long-term survival. More effective treatments are needed for subsets of patients with unfavorable biology tumors.